Latest Regulatory News

Sonic Healthcare has delivered solid FY 2025 results, meeting EBITDA guidance with 5% organic revenue growth and setting the stage for up to 19% EPS growth in FY 2026, driven by strategic acquisitions and operational synergies.

Sierra Nevada Gold (ASX – SNX) has qualified to bid for exploration licenses in Saudi Arabia’s Arabian Shield, leveraging its regional expertise to tap into a promising new frontier aligned with the Kingdom’s Vision 2030.

Baby Bunting Group confirms its FY25 financial results align with prior guidance and analyst expectations, addressing ASX queries on disclosure timing amid notable share price movements.

Downer EDI Limited has announced an on-market buy-back of up to 33.6 million ordinary shares, set to run from September 2025 through June 2026. The move signals a strategic capital management initiative without requiring shareholder approval.

SkyCity Entertainment Group reports a 5% revenue decline in FY25 amid economic headwinds and elevated investments, announcing a $240 million equity raise to bolster its balance sheet ahead of the NZICC opening and online gaming launch.

Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.

Diablo Resources is progressing exploration at its Phoenix Copper Project in Utah, targeting copper mineralisation near the producing Lisbon Valley Mine. Assay results from ongoing drilling and sampling are expected soon, supported by streamlined US permitting.

Tryptamine Therapeutics has secured an exclusive agreement with leading neuroscientists to develop a novel EEG-based brain entropy biomarker aimed at enhancing precision psychiatry for its psychedelic drug TRP-8803.

Downer EDI Limited reported a robust FY25 with a 33% rise in underlying NPATA and announced a $230 million share buy-back, underscoring confidence in its transformation and growth outlook. The company’s disciplined portfolio simplification and operational improvements set the stage for steady FY26 performance despite short-term market softness.

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Sonic Healthcare reported solid FY2025 results with revenue up 7.6% and a steady profit increase, while declaring a 63-cent final dividend. The company’s recent German acquisition and ongoing synergy efforts set the stage for robust earnings growth in FY2026.